BioSpace News Archive

LambdaVision announced it secured the first closing of its seed round being led by Aurelia Foundry Fund, a fund spun out of MIT. The round also includes investment from Boryung, a publicly listed Korean pharmaceutical company, and E2MC Ventures.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.

The Foundation for the National Institutes of Health announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus.

Intelligent Bio Solutions Inc. announced the successful recruitment and commencement of screening for subjects in its pharmacokinetic study, a critical component of the Company’s FDA 510 regulatory pathway for clearance.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”) today announced that management will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference.

Tris Pharma, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system (CNS) stimulant medications in pediatric patients six years and older.

Tandem Diabetes Care, Inc. and Dexcom, Inc., announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring Systems.

Jaguar Health, Inc. today announced that the company’s out-licensing agreement with Magdalena Biosciences, Inc. (“Magdalena”), the joint venture formed by Jaguar and Filament Health Corp.

Tharimmune, Inc. announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego.

MannKind Corporation announced that it has agreed to in-license iSPERSE™ technology from Pulmatrix for certain indications in exchange for an out-license of MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine for migraine treatment.